

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Levamisole / Oxclozanide Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Reproductive toxicity : Category 2

Short-term (acute) aquatic hazard : Category 2

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements :

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P273 Avoid release to the environment.

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version
8.0

Revision Date:
2025/04/14

SDS Number:
5360099-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Kaolin	1332-58-7	>= 1 - < 10	1-26
oxclozanide	2277-92-1	>= 3 - < 10	9-1297
levamisole hydrochloride	16595-80-5	>= 1 - < 10	-
Citric acid	77-92-9	>= 1 - < 10	2-1318

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Most important symptoms and effects, both acute and delayed	Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. Suspected of damaging the unborn child.
Protection of first-aiders	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	None known.
Specific hazards during fire-fighting	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	Carbon oxides Chlorine compounds Nitrogen oxides (NO _x)
Specific extinguishing methods	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/09/28
8.0 2025/04/14 5360099-00013 Date of first issue: 2019/12/19

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Concentra- tion standard / Permissible con- centration	Basis
Kaolin	1332-58-7	OEL-M (Respirable dust)	0.5 mg/m ³	JP OEL JSOH
		OEL-M (Total dust)	2 mg/m ³	JP OEL JSOH
		TWA (Res- pirable par- ticulate mat- ter)	2 mg/m ³	ACGIH
oxyclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal
		Further information: Skin		
			Wipe limit	200 µg/100 cm ²
				Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
Hand protection

Material : Chemical-resistant gloves

Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Skin and body protection : potential for direct contact to the face with dusts, mists, or aerosols.
Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : liquid
Colour : No data available
Odour : No data available
Odour Threshold : No data available
Melting point/freezing point : No data available
Boiling point, initial boiling point and boiling range : No data available
Flammability (solid, gas) : Not applicable
Flammability (liquids) : No data available
Lower explosion limit and upper explosion limit / flammability limit
Upper explosion limit / Up- : No data available
per flammability limit
Lower explosion limit / : No data available
Lower flammability limit
Flash point : No data available
Decomposition temperature : No data available
pH : No data available
Evaporation rate : No data available
Auto-ignition temperature : No data available
Viscosity
Viscosity, kinematic : No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Vapour pressure : No data available

Density and / or relative density
Relative density : No data available

Density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Kaolin:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

oxyclozanide:

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg
Application Route: Intravenous

levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Kaolin:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

oxyclozanide:

Remarks : Not classified due to lack of data.

levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

||Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Kaolin:

||Species : Rabbit
||Result : No eye irritation

oxyclozanide:

||Remarks : Not classified due to lack of data.

levamisole hydrochloride:

||Remarks : No data available

Citric acid:

||Species : Rabbit
||Result : Irritation to eyes, reversing within 21 days
||Method : OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

oxyclozanide:

||Exposure routes : Dermal
||Remarks : Not classified due to lack of data.

levamisole hydrochloride:

||Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

oxyclozanide:

||Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||Result: negative
||Test Type: Chromosomal aberration

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

		Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.
levamisole hydrochloride:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: negative
Citric acid:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: in vitro micronucleus test Result: positive
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Carcinogenicity

Not classified based on available information.

Components:

oxyclozanide:

||| Remarks : Not classified due to lack of data.

Levamisole / Oxyclozanide FormulationVersion
8.0Revision Date:
2025/04/14SDS Number:
5360099-00013Date of last issue: 2024/09/28
Date of first issue: 2019/12/19**levamisole hydrochloride:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	80 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**oxyclozanide:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity, No teratogenic effects, No effects on fertility
Effects on foetal develop-	:	Test Type: Development

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/09/28
8.0 2025/04/14 5360099-00013 Date of first issue: 2019/12/19

ment	<p>Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity, No teratogenic effects</p> <p>Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects</p> <p>Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity, Skeletal malformations</p>
Reproductive toxicity - Assessment	: Suspected of damaging the unborn child.
levamisole hydrochloride:	
Effects on fertility	: Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.
Citric acid:	
Effects on foetal development	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
STOT - single exposure	
Not classified based on available information.	

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version
8.0

Revision Date:
2025/04/14

SDS Number:
5360099-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Components:

oxyclozanide:

Exposure routes	:	Oral
Target Organs	:	Central nervous system
Assessment	:	May cause damage to organs.

Citric acid:

Assessment	:	May cause respiratory irritation.
------------	---	-----------------------------------

STOT - repeated exposure

Not classified based on available information.

Components:

oxyclozanide:

Target Organs	:	Brain, Liver
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

levamisole hydrochloride:

Target Organs	:	Blood, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

oxyclozanide:

Species	:	Rat
NOAEL	:	9 mg/kg
LOAEL	:	44.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects

Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

levamisole hydrochloride:

Species	:	Rat
NOAEL	:	2.5 mg/kg

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Blood

Species : Dog
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 3 Months

Citric acid:

Species : Rat
NOAEL : 4,000 mg/kg
LOAEL : 8,000 mg/kg
Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Components:

oxclozanide:

Not applicable

Experience with human exposure

Components:

oxclozanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

oxclozanide:

Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

M-Factor (Acute aquatic toxicity) : 1
M-Factor (Chronic aquatic toxicity) : 1

levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Persistence and degradability**Components:****oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

Citric acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential**Components:****oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n-

log Pow: -1.72

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

||| octanol/water

Mobility in soil

Components:

oxyclozanide:

||| Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(oxyclozanide)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
Levamisole hydrochloride	>=1 - <10	From April 1st, 2025

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
Levamisole hydrochloride	From April 1st, 2025

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

SAFETY DATA SHEET



Levamisole / Oxyclozanide Formulation

Version 8.0 Revision Date: 2025/04/14 SDS Number: 5360099-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Noxious liquid substance(Category Z)
Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)
Not applicable
Specific Narcotic or Psychotropic Raw Material (Export / Import permission)
Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
JP OEL JSOH : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits
ACGIH / TWA : 8-hour, time-weighted average
JP OEL JSOH / OEL-M : Occupational Exposure Limit-Mean

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-

SAFETY DATA SHEET



Levamisole / Oxclozanide Formulation

Version
8.0

Revision Date:
2025/04/14

SDS Number:
5360099-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN